There is a lack of data on incidental hepatocellular carcinoma (iHCC) in the setting of liver transplantation (LT) in human immunodeficiency virus (HIV)-infected patients. This study aims to describe the frequency, histopathological characteristics, and outcomes of HIV1 LT recipients with iHCC from a Spanish multicenter cohort in comparison with a matched cohort of LT patients without HIV infection. A total of 15 (6%) out of 271 patients with HIV infection who received LT in Spain from 2002 to 2012 and 38 (5%) out of the 811 HIV-counterparts presented iHCC in liver explants (P 5 0.58). Patients with iHCC constitute the present study population. All patients also had hepatitis C virus (HCV)-related cirrhosis. There were no significant differences in histopathological features of iHCC between the 2 groups. Most patients showed a small number and size of tumoral nodules, and few patients had satellite nodules, microvascular invasion, or poorly differentiated tumors. After a median follow-up of 49 months, no patient developed hepatocellular carcinoma (HCC) recurrence after LT. HIV1 LT recipients tended to have lower survival than their HIV-counterparts at 1 (73% versus 92%), 3 (67% versus 84%), and 5 years (50% versus 80%; P 5 0.06). There was also a trend to a higher frequency of HCV recurrence as a cause of death in the former (33% versus 10%; P 5 0.097). In conclusion, among LT recipients for HCV-related cirrhosis, the incidence and histopathological features of iHCC in HIV1 and HIV-patients were similar. However, post-LT survival was lower in HIV1 patients probably because of a more aggressive HCV recurrence.
antiretroviral therapy (cART), particularly in those patients with hepatitis C virus (HCV) coinfection. (1) (2) (3) Liver transplantation (LT) is the only effective treatment for those patients with decompensated cirrhosis and/or hepatocellular carcinoma (HCC), and HIV infection is not a contraindication for suitable candidates who fulfill LT criteria. (4) Therefore, LT is increasingly necessary in the setting of HIV infection. (4) Many reports have assessed the incidence and main outcomes of incidental hepatocellular carcinoma (iHCC) in patients without HIV infection. (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) The presence of iHCC in explanted liver varies widely between 1% and 17%, (5, 6, (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) and controversy exists concerning its impact on the outcomes of LT recipients (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) with a highly variable incidence of tumor recurrence after LT reported in studies addressing this issue, ranging from 0% to 33%. (5, 6, 8, 9, (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) Conversely, there is no information on iHCC in the setting of HIV infection. Although a recent study showed that the main characteristics and outcomes of HIV1 patients undergoing LT for HCC known at the time of the transplant are comparable with those observed in non-HIV1 patients, (22) similar data regarding HIV1 LT recipients with iHCC are lacking. Therefore, since neither the incidence and characteristics of iHCC nor the risk of tumor recurrence in HIV1 LT patients have been established, particularly in comparison with HIV-LT recipients, the prognosis of the former remains uncertain.
This article aims to describe the frequency, histopathological characteristics, and outcomes of HIV1 LT recipients with iHCC from a multicenter nationwide cohort and compare them with those LT recipients with iHCC from a matched cohort of patients without HIV infection.
Patients and Methods

STUDY DESIGN AND PATIENTS
All patients with iHCC were selected from a nationwide multicenter prospective cohort study based on all consecutive adult patients with HIV infection who underwent LT between 2002 and 2012 in Spain and were followed until July 2014. The patients from this cohort were matched with LT recipients without HIV infection (1:3) considering center, calendar year of LT (61 year), age (612 years), sex, liver disease etiology, and presence of HCC. (23) TRANSPLANT CRITERIA All patients with HIV infection had to fulfill the described HIV-related inclusion criteria for LT. (23) The liver disease-related criteria for enlisting HIV1 patients for LT were the same as those recommended for LT candidates without HIV infection and were previously detailed. (22, 23) Concerning HCC, patients with a single tumor 5 cm or multiple tumors (up to 3 nodules) 3 cm with no macrovascular invasion or extrahepatic spread were accepted for LT enlisting. In all participating centers, as a part of the HCC surveillance, after enlisting for LT, radiological imaging was performed with a minimum frequency of 3 months until LT in patients with HCC and with a minimum frequency of 6 months in the remaining patients. (22) iHCC was defined as a pathologically proven HCC in the explanted liver which had not been diagnosed before LT with imaging studies. All patients with iHCC constituted the present study cohort. Additional supporting information may be found in the online version of this article.
The main operational characteristics of the present study have already been described in detail elsewhere. (23) The study was approved by the institutional review boards of all the participating sites.
POSTTRANSPLANT MANAGEMENT
cART was resumed when patients were able to tolerate oral medication. Postoperative immunosuppression was the same for LT recipients with and without HIV infection and was based on local protocols consisting of cyclosporine-or tacrolimus-based regimens. A total of 10 of the 15 (66%) participant centers reporting LT-recipient patients with iHCC performed post-LT surveillance protocols for HCC recurrence. These protocols consisted of periodic (3-6 months) imaging studies and alpha-fetoprotein measurements for at least the first 3 years after LT. (24) The remaining 5 participant centers did not perform any protocol of HCC recurrence surveillance. (24) 
STATISTICAL ANALYSIS
Continuous variables were expressed as median and interquartile range (IQR) and were compared using nonparametric test (Mann-Whitney U test). Categorical variables were expressed as a percentage and compared using either the chi-square test or Fisher's exact test. Patient survival rates were estimated with the Kaplan-Meier method and compared with the logrank test. Death from any cause was treated as a failure. For patients who were alive, time was censored at the date of the last visit. A 2-sided P value < 0.05 was considered as indicating statistical significance. All statistical analyses were carried out using the STATA package, version 9.2 (StataCorp, College Station, TX).
Results
A total of 15 (6%) out of 271 LT recipients with HIV infection and 38 (5%) out of the 811 HIV-counterparts presented with iHCC in liver explants (P 5 0.58). Table 1 shows the main baseline characteristics of patients from the 2 populations. Men accounted for 85%, and HCV cirrhosis was the primary liver disease in all recipients. HCV genotype 1 was the most common (64% versus 74% in HIV1 and HIV-recipients, respectively; P 5 0.48). All HIV1 recipients were on cART, and most of them had plasma HIV-1 viral loads below the detection limit at enlisting (93%). Median (IQR) CD4 cell count/mm 3 was 330 (178-518). Intravenous drug use was the most frequent mode of HIV-1 infection acquisition (93%). There were no differences in the HCC pathological features of the explanted liver between the 2 groups. The number and size of tumoral nodules were small in most patients. Very few patients showed satellite nodules or microvascular invasion, and all but 1 patient had tumors with well/ moderate histological differentiation grade according to the Edmondson grading system.
As shown in Table 2 , after a median (IQR) followup of 49 (28-82) months, not a single patient of the whole cohort developed HCC recurrence after LT. Overall 15 (28%) patients died: 7 (47%) HIV1 and 8 (21%) HIV-patients (P 5 0.06). The main cause of death in both groups was HCV recurrence, although it tended to be more frequent in the HIV1 population: 33% versus 10% in the HIV-population (P 5 0.097). Figure 1 shows the cumulative survival in the 2 cohorts. A trend toward a lower survival probability was observed among HIV1 LT recipients when compared with their counterparts without HIV infection, with Kaplan-Meier estimates (95% confidence interval) of 73% (50%-93%) versus 92% (77%-97%), respectively, at 1 year, 67% (37%-85%) versus 84% (68%-92%) at 3 years, and 50% (22%-73%) versus 80% (63%-90%) at 5 years (P 5 0.06).
A total of 8 (53%) out of the 15 HIV1 patients and 23 (61%) out of the 38 HIV-patients received antiviral treatment for HCV recurrence. Peginterferon plus ribavirin was administered in 30 patients and sofosbuvir plus ribavirin in 1 patient. Sustained virological response (SVR) was achieved in 2 (25%) HIV1 patients and 16 (70%) HIV-patients (P 5 0.04). In the 18 patients with SVR and in the 13 patients without SVR, the overall mortality rates were 6% versus 54%, respectively (P 5 0.004).
Discussion
According to the objectives of our study, the most remarkable findings were the following: 1. The cohort of HIV1 LT recipients showed a similar frequency of iHCC as the matched control cohort of HIV-patients. 2. Histopathological tumor characteristics were also similar in the 2 cohorts, with low tumor burden and aggressiveness in most patients. 3. During a reasonably prolonged follow-up after LT (median value approximately 4 years), both populations had an identical incidence of tumor recurrence, which was nil. 4. Despite these comparable results in relation to iHCC in both groups, a clear trend to a lower survival in HIV1 patients was observed.
The incidence of iHCC in LT recipients with and without HIV infection was very similar: 6% and 5%, respectively. Although some authors reported an incidence of iHCC higher than 15% in non-HIV1 LT patients, (15, 16) most of the previous reports observed a frequency of iHCC approximately 5% or even lower. (5, 6, 8, 9, 11) Hence, our results are congruent with the existing evidence.
HIV1 and HIV-patients also exhibit similar histopathologic findings in the explanted livers. In both groups, most tumors consisted of a single nodule (>70%); most patients had lesions 20 mm (>80%) and fell within the Milan and the University of California, San Francisco (UCSF) criteria (>90%). Additionally, well/moderate differentiated tumors accounted for the vast majority of patients from the 2 groups (>90%) and satellite nodules and microvascular invasion were observed in few patients. All these data reflect a low tumor burden and aggressiveness in our HIV1 and HIV-LT recipients with iHCC and may explain the absence of tumor recurrence after LT in our series since high extension, poor differentiation, and particularly microvascular invasion have been identified as strong risk factors for tumor recurrence after LT for HCC in different studies. (9, 21, 22, 25, 26) In previous reports on iHCC, a large variability in histopathological features has been found, ranging from tumors with characteristics similar to those observed in our study (6, 7, 11) to more extended and aggressive tumors. (5, 8, 10, 21, 27) The incidence of tumor recurrence observed in different studies involving LT patients with iHCC has also been very variable, with studies reporting a 0% incidence, (6, 12, 15, 18, 20) as in our investigation, and studies with a higher incidence, up to 33%. (5, 8, 9, 13, 14, 16, 17, 19, 21) In our study, despite the similar characteristics of iHCC and the underlying cirrhosis and the absence of tumor recurrence in patients with and without HIV infection, there was an evident trend, almost statistically significant (P 5 0.062), to a lower survival in the former: 73% versus 92% at 1 year after LT, 67% versus 84% at 3 years, and 50% versus 80% at 5 years. A similar difference in post-LT survival has been observed in 2 other studies comparing HIV1 and HIV-patients who underwent LT for HCV-related cirrhosis, as in our current series in which 100% of patients had cirrhosis caused by HCV. In 1 of these studies, the 5-year survival after LT was 51% in HIV-HCV coinfected patients and 81% in HCV monoinfected patients, (28) and in the other study, the corresponding figures were 54% versus 71%, respectively. (23) In these 2 investigations, the different survival was mainly related to a more aggressive HCV recurrence in the HIV1 population. (23, 28) In the present study, we observed that HCV recurrence was the most frequent cause of death in HIV1 and HIVpatients, but was 3 times more frequent in the former (33% versus 10%, respectively; difference not statistically significant probably due to the small number of patients, with a P value of 0.097), which is in agreement with the previously published data. Notably, as expected on the basis of a previous report focusing on the treatment of HCV recurrence with peginterferon and ribavirin in LT patients with and without HIV coinfection, (29) our HIV1 patients had a poorer response to anti-HCV therapy, almost exclusively consisting of peginterferon and ribavirin, as compared with HIV-patients, with SVR rates of 25% and 70%, respectively. Because a substantial proportion of patients without SVR died from HCV recurrence, the low SVR achieved in HIV1 patients could have contributed to the trend toward a worse outcome in these patients. Hopefully, the use of direct antiviral agents against HCV will drastically modify this trend to a worse outcome in HIV1 patients.
Post-LT survival in our HIV1 patients with iHCC was lower than that observed in a recently published article (22) involving LT recipients with HIV infection and HCC known before transplantation: 50% versus 67% at 5 years, respectively. Both series have been selected from the Spanish cohort of HIV1 LT patients mentioned in the Patients and Methods section. It is likely that this different survival was due to the poorer status of the underlying cirrhosis in LT recipients with iHCC, reflected by a higher Model for End-Stage Liver Disease (MELD) score, with a median value at the time of LT of 17 in patients with iHCC versus 10 in patients with known HCC. (22) A more advanced liver disease, assessed by the MELD score, has been identified in 2 previous studies as a bad independent prognostic factor in HIV1 patients who received LT predominantly for cirrhosis. (23, 28) The main limitation of our study is its small sample size, which precludes taking robust conclusions. To the best of our knowledge, however, this is the only study including HIV1 LT recipients with iHCC and a matched HIV-control. Another possible limitation could be the absence of a standardized protocol for HCC recurrence surveillance since some participating centers did not perform any specific surveillance. Nevertheless, the incidence of tumor recurrence was nil in centers with and without such a protocol. Likewise, in a previous study involving LT recipients with HCC known before transplantation, the rates of tumor recurrence and survival after HCC recurrence were also comparable between centers with and without a surveillance protocol. (22) In summary, among patients with LT for HCV-related cirrhosis the incidence of iHCC and the histopathological findings in the liver explants were similar in HIV1 LT recipients and in their HIV2 counterparts. No patient from the 2 populations developed tumor recurrence. This fact could be explained by the low tumor burden and aggressiveness observed in most patients. HIV1 LT recipients with iHCC, however, tended to have lower survival than recipients without HIV infection, probably because of an increased death rate due to HCV recurrence in the former.
